drugset
drugset / Trial / NCT03327857

Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease

NCT03327857 ↗

Phase 1 Completed 37 enrolled AltruBio Inc.
NaSingle-groupOpen-labelTreatment

Summary

A Phase I study to establish the pharmacokinetics, pharmacodynamics, safety and efficacy profiles of Neihulizumab in patients with steroid-refractory or treatment refractory acute graft-versus-host disease (SR/TR-aGVHD)

Timeline

Start
2018-05-31
Primary completion
2022-09-30
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Neihulizumab Monoclonal antibody — Intravenous

Indications

acute graft versus host disease